Inhaled Nitric Oxide for New Borns at Hope's Child Development Center
Inhaled Nitric Oxide (INO)
Inhaled nitric oxide (INO) is a pulmonary play a prominent role in regulating vascular muscle tone. Treatment for hypoxemic respiratory failure amongst newly born infants it will persistent high pulmonary vascular pressure and resultant right-to-left shunting of blood. With current evidence showing that INO improves oxygenation and drops the combined outcome of fatality or need for extracorporeal membrane oxygenation in infants less than or at 35 weeks’ gestational age at birth. Proven in managing preterm infants under 35 weeks’ gestational age has not been established yet.
With evidence supporting the use of INO for infants under or at 35 weeks’ gestational age at birth with hypoxemic respiratory failure and do not respond to appropriate respiratory management. For infants with pulmonary disease, treatment includes optimizing tidal volume/pressure and the use of manoeuvres to recruit lung units such as a surfactant, high-frequency oscillatory ventilation and/or jet ventilation. Ideally, all new-born candidates for INO therapy should undergo an echocardiographic evaluation to rule out cyanotic congenital heart disease and to assess for pulmonary hypertension and cardiac function.